Relugolix for the treatment of uterine fibroids.

Article Details

Citation
Copy to clipboard

Barra F, Seca M, Della Corte L, Giampaolino P, Ferrero S

Relugolix for the treatment of uterine fibroids.

Drugs Today (Barc). 2019 Aug;55(8):503-512. doi: 10.1358/dot.2019.55.8.3020179.

PubMed ID
31461087 [ View in PubMed
]
Abstract

Uterine leiomyomas represent the most common form of benign gynecological tumors affecting 20-40% of women during their life. Several therapeutic options are available for treating these patients. The use of medical treatment for myomas has largely grown in the last years, in particular for women who would refuse, postpone or are not candidates for surgery. In the last years, the clinical investigation of gonadotropin-releasing hormone (GnRH) antagonists (GnRH-ants) has emerged. This class of drugs exerts pure competitive antagonistic activity on the GnRH receptor at the pituitary gland, producing an immediate stop in the release of gonadotropins and sex steroids. Relugolix is an orally active nonpeptide GnRH-ant, recently licensed for marketing in Japan for the treatment of symptoms related to uterine myomas. Currently, several phase III clinical trials are ongoing to evaluate this molecule in this setting in the U.S. and Europe.

DrugBank Data that Cites this Article

Drugs